Avalo Therapeutics, Inc. (AVTX) Cash Flow Statement
Avalo Therapeutics, Inc. (AVTX) generated -$68.3M of operating cash flow over the twelve months to 2026-06-30, spent $0 on capital expenditure and had free cash flow of -$68.3M, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
AVTXAvalo Therapeutics, Inc.Follow AVTX — free
—
Price chart with a free account
- Market cap
- 371.7M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 4 Nov, in 11 days
| Line | FY2017 Dec 17 | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 12.6 | -3.1 | -19.1 | -40.5 | -70.9 | -26.8 | -30.7 | -49.1 | -51.5 | -68.3 | |
| Capital expenditure | 0.0 | 0.6 | 0.3 | 0.1 | 0.1 | 0.1 | 0.0 | 0.0 | 0.0 | -0.0 | |
| Free cash flow | 12.6 | -3.7 | -19.4 | -40.6 | -71.0 | -26.8 | -30.7 | -49.1 | -51.5 | -68.3 | |
| Stock-based compensation | 1.2 | 2.4 | 2.5 | 6.8 | 8.2 | 7.6 | 3.5 | 5.9 | 13.6 | — |
USD millions · SEC XBRL
Avalo Therapeutics, Inc. — questions
- What is Avalo Therapeutics, Inc.'s operating cash flow?
- -$68.3M over the twelve months to 2026-06-30.
- How much does Avalo Therapeutics, Inc. spend on capital expenditure?
- $0 over the twelve months to 2026-06-30.
- What is Avalo Therapeutics, Inc.'s free cash flow?
- -$68.3M over the twelve months to 2026-06-30: operating cash flow minus capital expenditure.
Every figure on this page comes from Avalo Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.